Ultivue

What Ultivue does

Ultivue, Inc. is a privately held biotechnology company founded in 2015 and headquartered in Cambridge, Massachusetts, operating in the spatial biology market. The company's core technology is InSituPlex, a multiplexed immunofluorescence assay that enables spatial proteomic analysis of tissue, allowing researchers to map multiple protein biomarkers at single-cell resolution within intact tissue samples, including FFPE specimens. Its primary customer base is pharmaceutical and biotechnology research organizations engaged in immuno-oncology biomarker discovery and companion diagnostics development, where the platform is positioned to identify patient sub-populations that respond to immune checkpoint inhibitors and adoptive T-cell therapies.

Ultivue announced a merger with Vizgen to unify spatial biology capabilities, integrating Vizgen's MERFISH spatial transcriptomics platform (delivered via the MERSCOPE Ultra instrument) with Ultivue's InSituPlex protein assays. The combined portfolio spans instruments, reagents and consumables, core and custom biomarker panels (OmniVUE and U-VUE), and AI-enhanced analysis software (STARVUE and MERSCOPE Vizualizer), supported by a global footprint of 200+ MERSCOPE platforms and 400+ peer-reviewed MERFISH publications. Applications explicitly span neuroscience, oncology, immunology, and cell atlasing.

The company's revenue mechanics reflect a life sciences tools model, combining instrument sales (MERSCOPE Ultra), recurring consumables and reagents, custom and catalog biomarker panels, and service offerings (Spatial Transcriptomics and Spatial Omics Services). The company is venture-backed, with disclosed funding rounds totaling roughly $110M across Series A through a 2021 Series C (Northpond Ventures, ARCH Venture Partners, Applied Ventures, among others), and a 2024 SEC Form D exempt offering targeting an additional ~$15M of capital. Pricing is not publicly disclosed. The company has 51–100 employees and remains privately held, with no public ticker.

Name

Ultivue

Legal name

Ultivue, Inc.

Website

https://ultivue.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Ultivue is a Cambridge-based spatial biology company that develops the InSituPlex multiplexed immunofluorescence platform for spatial proteomics in tissue. Following its announced merger with Vizgen, it offers an integrated spatial multiomics portfolio spanning MERFISH transcriptomics, proteomics, and AI-driven analysis, serving pharma, biotech, and academic researchers in immuno-oncology and companion diagnostics.

Ownership category

akta.pro rank

Product category

Spatial Biology Instruments and Assays

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)

akta.pro secondary industries

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Spatial biology
• Multiplexed immunofluorescence
• Spatial proteomics
• Tissue imaging assays
• Biomarker analysis

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Core offering

Ultivue develops and sells the InSituPlex multiplexed immunofluorescence assay platform for spatial proteomics, enabling single-cell, in-situ quantification of multiple protein biomarkers in tissue samples including FFPE. Following its announced merger with Vizgen, the combined company also offers MERFISH-based spatial transcriptomics on the MERSCOPE Ultra instrument, custom and core biomarker panels, STARVUE analysis software, and contract spatial omics services for pharmaceutical and academic researchers.

Product overview

Ultivue is a biotechnology company incorporated in Delaware and based in Cambridge, Massachusetts, operating in the spatial biology market. According to a market report, Ultivue announced a merger with Vizgen to unify their spatial biology capabilities. No specific product names, modules, or product architecture details were available in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

• InSituPlex Multiplexed Immunofluorescence Assays Pathology-grade multiplexed protein detection assays for FFPE tissue, enabling simultaneous quantification of multiple biomarkers at single-cell and spatial resolution; intended for pharmaceutical and biotech immuno-oncology researchers and clinical laboratories.
• MERSCOPE Ultra Spatial Transcriptomics Platform Instrument platform for spatial transcriptomics using MERFISH 2.0 chemistry, providing single-cell in-situ RNA quantification across large tissue areas; targeted at pharma, biotech, and academic translational researchers.
• MERSCOPE Vizualizer Software Visualization and analysis software for spatial transcriptomics datasets, enabling researchers to explore single-cell RNA maps generated on MERSCOPE instruments.
• Core Biomarker Panels (OmniVUE) Pre-validated multiplexed biomarker panels for InSituPlex spatial proteomics, providing reproducible, FFPE-ready, AI-enhanced analytics for common immuno-oncology and tumor microenvironment targets.
• Custom Biomarker Panels (U-VUE) Customer-defined multiplexed biomarker panels for InSituPlex, allowing researchers to design sensitive, reproducible, FFPE-ready assays for their specific targets of interest.
• STARVUE Single-Cell Spatial Analysis Software AI-driven single-cell and spatial analysis software for multiomics datasets, supporting interpretation of MERFISH and InSituPlex readouts.
• Gene Panels Catalog and configurable gene panels for MERFISH-based spatial transcriptomics, used with the MERSCOPE platform to profile RNA targets in tissue.
• Reagents and Consumables Reagents, kits, and consumables required to run MERSCOPE spatial transcriptomics workflows and InSituPlex spatial proteomics assays, sold as part of the instrument-and-consumable business model.
• Spatial Transcriptomics Services Service offering where the company performs spatial transcriptomics experiments and analysis on customer samples using MERFISH 2.0 and supporting pipelines, delivering reproducible RNA readouts and a concise report.
• Spatial Proteomics Assay Development Services Custom assay development and spatial proteomics services in which the company designs and runs InSituPlex assays for customers, including biomarker panel design and validation.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• VizgenflagshipStrategic or Co-development PartnerVizgen and Ultivue announced a merger to unify their spatial biology capabilities. The combined entity will integrate Vizgen's MERFISH spatial transcriptomics platform with Ultivue's InSituPlex multiplexed immunofluorescence technology to create a comprehensive spatial multiomics offering.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Standard BioTools (formerly Fluidigm): Standard BioTools offers the Hyperion imaging mass cytometry system for highly multiplexed tissue imaging, an alternative spatial proteomics modality competing for translational research budgets alongside InSituPlex.
• Resolve Biosciences: Resolve Biosciences develops Molecular Cartography single-cell spatial transcriptomics for subcellular resolution, representing an emerging competitor in the same spatial biology market as Ultivue/Vizgen.
• Rebus Biosystems: Rebus Biosystems offers the Rebus Esper spatial omics platform with single-molecule resolution, targeting similar translational and pharma research customers with an alternative spatial transcriptomics approach.
• Ionpath (now part of Standard BioTools): Ionpath develops MIBI (multiplexed ion beam imaging) for high-plex spatial proteomics, an emerging technology alternative that competes for translational immuno-oncology and pharma research customers alongside InSituPlex.

Direct peers

• 10x Genomics: 10x Genomics offers Visium and Xenium spatial transcriptomics platforms alongside Chromium single-cell products, directly competing in the same spatial biology market as Ultivue and Vizgen for pharma, translational, and academic customers.
• Vizgen: Vizgen develops MERFISH-based spatial transcriptomics platforms (MERSCOPE) and is now merging with Ultivue to form an integrated spatial multiomics company. Direct overlap in spatial biology tools serving translational and pharma research customers.
• Akoya Biosciences: Akoya Biosciences offers the PhenoCycler (CODEX) multiplexed immunofluorescence platform and PhenoImager HT, directly competing with Ultivue's InSituPlex in spatial proteomics for immuno-oncology and translational research.
• Lunaphore (acquired by Bio-Techne): Lunaphore's COMET multiplexed staining platform is a direct competitor to Ultivue's InSituPlex for automated, high-throughput multiplexed tissue biomarker analysis in translational and clinical research labs.

Broad incumbents

• Bio-Techne: Bio-Techne provides RNAscope in situ hybridization and the GeoMx digital spatial profiling platform via its Diagnostics & Spatial Biology segment, competing with Ultivue in tissue-based biomarker analysis for research and clinical applications.
• Bruker (acquired NanoString): Bruker acquired NanoString Technologies and now sells the CosMx SMI spatial molecular imager alongside a broad life-science instrument portfolio, making it a scaled incumbent competitor in spatial transcriptomics and proteomics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

• Xx.com/Ultivue
• Facebookfacebook.com/100244404759659
• LinkedInlinkedin.com/company/ultivue

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ultivue